By studying case reports on the development of inflammatory bowel disease lesions in psoriasis patients treated with IL-17 inhibitors, along with a case presentation, we aim at increasing the awareness of the need for close follow-up of these patients. This evidence concerns the gene IL17A and psoriasis.